Changes for page Neurodiagnoses

Last modified by manuelmenendez on 2025/03/03 22:46
From version 7.1
edited by manuelmenendez
on 2025/01/27 23:21
Change comment: There is no comment for this version
To version 5.1
edited by manuelmenendez
on 2025/01/27 23:04
Change comment: There is no comment for this version

Summary

Details

Page properties
Content
... ... @@ -2,10 +2,9 @@
2 2  (((
3 3  (% class="container" %)
4 4  (((
5 -= //A new tridimensional diagnostic framework for CNS conditions// =
5 += Neurodiagnoses =
6 6  
7 -This project is focused on developing a novel nosological and diagnostic framework for neurological diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies.
8 -We aim to create a structured, interpretable, and scalable diagnostic tool.
7 +This project is focused on developing a novel nosological and diagnostic framework for neurological diseases. Using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies, we aim to create a structured, interpretable, and scalable diagnostic tool.
9 9  )))
10 10  )))
11 11  
... ... @@ -13,70 +13,8 @@
13 13  (((
14 14  (% class="col-xs-12 col-sm-8" %)
15 15  (((
16 -= What is this about and what can I find here? =
15 += What can I find here? =
17 17  
18 -==== **Overview** ====
19 -
20 -The //Tridimensional Diagnostic Framework// redefines how neurodegenerative diseases (NDDs) are classified by focusing on:
21 -
22 -* **Axis 1**: Etiology (genetic/sporadic and environmental factors).
23 -* **Axis 2**: Molecular Markers (biomarkers and proteinopathies).
24 -* **Axis 3**: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system).
25 -
26 -This methodology enables:
27 -
28 -* Greater precision in diagnosis.
29 -* Integration of incomplete datasets using AI-driven probabilistic modeling.
30 -* Stratification of patients for personalized treatment.
31 -
32 -==== **Diagnostic Axes** ====
33 -
34 -* (((
35 -**Axis 1: Etiology**
36 -
37 -* //Description//: Focuses on genetic and sporadic causes, identifying risk factors and potential triggers.
38 -* //Examples//: APOE ε4 as a genetic risk factor, or cardiovascular health affecting NDD progression.
39 -* //Tests//: Genetic testing, lifestyle and cardiovascular screening.
40 -)))
41 -* (((
42 -**Axis 2: Molecular Markers**
43 -
44 -* //Description//: Analyzes primary (amyloid-beta, tau) and secondary biomarkers (NFL, GFAP) for tracking disease progression.
45 -* //Examples//: CSF amyloid-beta concentrations to confirm Alzheimer’s pathology.
46 -* //Tests//: Blood/CSF biomarkers, PET imaging (Tau-PET, Amyloid-PET).
47 -)))
48 -* (((
49 -**Axis 3: Neuroanatomoclinical**
50 -
51 -* //Description//: Links clinical symptoms to neuroanatomical changes, such as atrophy or functional impairments.
52 -* //Examples//: Hippocampal atrophy correlating with memory deficits.
53 -* //Tests//: MRI volumetrics, FDG-PET, neuropsychological evaluations.
54 -)))
55 -
56 -==== **Case Studies** ====
57 -
58 -1. (((
59 -**Sporadic Alzheimer’s Disease**:
60 -
61 -* Axis 1: Sporadic (ApoE4, poor sleep habits).
62 -* Axis 2: Amyloid-beta plaques, elevated NFL.
63 -* Axis 3: Right hippocampus atrophy (visual memory loss).
64 -)))
65 -1. (((
66 -**Genetic Parkinson’s Disease**:
67 -
68 -* Axis 1: Genetic (LRRK2 mutation).
69 -* Axis 2: Alpha-synuclein aggregation.
70 -* Axis 3: Substantia nigra degeneration (motor dysfunction).
71 -)))
72 -
73 -==== **Applications** ====
74 -
75 -This system enhances:
76 -
77 -* **Research**: By stratifying patients, it reduces cohort heterogeneity in clinical trials.
78 -* **Clinical Practice**: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking.
79 -
80 80  == Who has access? ==
81 81  
82 82  We welcome contributions from the global community. Let’s build the future of neurological diagnostics together!